Autoimmune Hypoglycemia Expands the Biological Spectrum of HHV8+ Multicentric Castleman Disease

Overview

Journal Blood Adv

Specialty Hematology

Date 2021 Mar 31

PMID 33787862

Citations 1

Authors

Pierre Arnautou

Martine Auclair

Soraya Fellahi

Clara Bouche

Claire Fieschi

Elias Barrak

Viviane Queyrel-Moranne

Lucy Chaillous

Nicolas Blin

Marion Malphettes

Jehane Fadlallah

Remi Bertinchamp

Laurence Gerard

Djaouida Bengoufa

Lionel Galicier

Eric Oksenhendler

Corinne Vigouroux

David Boutboul

Affiliations

Soon will be listed here.

Citing Articles

HHV8-Positive Multicentric Castleman's Disease and Thrombotic Thrombocytopenic Purpura among HIV-Positive Patients.

Pasquer R, Dieudonne Y, Decours P, Hinschberger O, Nicolae A, Martinot M Eur J Case Rep Intern Med. 2024; 11(3):004361.

PMID: 38455701 PMC: 10917415. DOI: 10.12890/2024_004361.

References

London J, Boutboul D, Agbalika F, Coppo P, Veyradier A, Gerard L . Autoimmune thrombotic thrombocytopenic purpura associated with HHV8-related Multicentric Castleman disease. Br J Haematol. 2016; 178(3):486-488. DOI: 10.1111/bjh.14152. View

Dons R, Havlik R, Taylor S, Baird K, CHERNICK S, Gorden P . Clinical disorders associated with autoantibodies to the insulin receptor. Simulation by passive transfer of immunoglobulins to rats. J Clin Invest. 1983; 72(3):1072-80. PMC: 1129275. DOI: 10.1172/JCI111032. View

Suematsu S, Matsuda T, Aozasa K, Akira S, Nakano N, Ohno S . IgG1 plasmacytosis in interleukin 6 transgenic mice. Proc Natl Acad Sci U S A. 1989; 86(19):7547-51. PMC: 298102. DOI: 10.1073/pnas.86.19.7547. View

Malek R, Chong A, Lupsa B, Lungu A, Cochran E, Soos M . Treatment of type B insulin resistance: a novel approach to reduce insulin receptor autoantibodies. J Clin Endocrinol Metab. 2010; 95(8):3641-7. PMC: 2913034. DOI: 10.1210/jc.2010-0167. View

Soulier J, GROLLET L, Oksenhendler E, Cacoub P, Cazals-Hatem D, Babinet P . Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood. 1995; 86(4):1276-80. View

Gerard L, Berezne A, Galicier L, Meignin V, Obadia M, de Castro N . Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman's disease: ANRS 117 CastlemaB Trial. J Clin Oncol. 2007; 25(22):3350-6. DOI: 10.1200/JCO.2007.10.6732. View

Hassman L, Ellison T, Kedes D . KSHV infects a subset of human tonsillar B cells, driving proliferation and plasmablast differentiation. J Clin Invest. 2011; 121(2):752-68. PMC: 3026728. DOI: 10.1172/JCI44185. View

Nicol S, Sabbah S, Brulois K, Jung J, Bell A, Hislop A . Primary B Lymphocytes Infected with Kaposi's Sarcoma-Associated Herpesvirus Can Be Expanded In Vitro and Are Recognized by LANA-Specific CD4+ T Cells. J Virol. 2016; 90(8):3849-3859. PMC: 4810529. DOI: 10.1128/JVI.02377-15. View

Kawashiri S, Kawakami A, Fujikawa K, Iwamoto N, Aramaki T, Tamai M . Type B insulin resistance complicated with systemic lupus erythematosus. Intern Med. 2010; 49(5):487-90. DOI: 10.2169/internalmedicine.49.2746. View

10.

Coll A, Thomas S, Mufti G . Rituximab therapy for the type B syndrome of severe insulin resistance. N Engl J Med. 2004; 350(3):310-1. DOI: 10.1056/NEJM200401153500324. View

11.

Peterson B, Frizzera G . Multicentric Castleman's disease. Semin Oncol. 1993; 20(6):636-47. View

12.

Braund W, Naylor B, Williamson D, Buley I, Clark A, Chapel H . Autoimmunity to insulin receptor and hypoglycaemia in patient with Hodgkin's disease. Lancet. 1987; 1(8527):237-40. DOI: 10.1016/s0140-6736(87)90063-8. View

13.

Manikas E, Isaac I, Semple R, Malek R, Fuhrer D, Moeller L . Successful treatment of type B insulin resistance with rituximab. J Clin Endocrinol Metab. 2015; 100(5):1719-22. PMC: 4422897. DOI: 10.1210/jc.2014-3552. View

14.

Arioglu E, Andewelt A, Diabo C, Bell M, Taylor S, Gorden P . Clinical course of the syndrome of autoantibodies to the insulin receptor (type B insulin resistance): a 28-year perspective. Medicine (Baltimore). 2002; 81(2):87-100. DOI: 10.1097/00005792-200203000-00001. View

15.

Oksenhendler E, Boutboul D, Fajgenbaum D, Mirouse A, Fieschi C, Malphettes M . The full spectrum of Castleman disease: 273 patients studied over 20 years. Br J Haematol. 2017; 180(2):206-216. DOI: 10.1111/bjh.15019. View

16.

Klubo-Gwiezdzinska J, Lange M, Cochran E, Semple R, Gewert C, Brown R . Combined Immunosuppressive Therapy Induces Remission in Patients With Severe Type B Insulin Resistance: A Prospective Cohort Study. Diabetes Care. 2018; 41(11):2353-2360. PMC: 6196834. DOI: 10.2337/dc18-0884. View

17.

Liminet C, Vouillarmet J, Chikh K, Disse E . Antibody-Mediated Insulin Resistance: When Insulin and Insulin Receptor Act as Autoantigens in Humans. Can J Diabetes. 2016; 40(5):462-465. DOI: 10.1016/j.jcjd.2016.02.007. View

18.

Codish S, Abu-Shakra M, Ariad S, Zirkin H, Yermiyahu T, Dupin N . Manifestations of three HHV-8-related diseases in an HIV-negative patient: immunoblastic variant multicentric Castleman's disease, primary effusion lymphoma, and Kaposi's sarcoma. Am J Hematol. 2000; 65(4):310-4. DOI: 10.1002/1096-8652(200012)65:4<310::aid-ajh11>3.0.co;2-g. View

19.

Kahn C, Flier J, Bar R, Archer J, Gorden P, Martin M . The syndromes of insulin resistance and acanthosis nigricans. Insulin-receptor disorders in man. N Engl J Med. 1976; 294(14):739-45. DOI: 10.1056/NEJM197604012941401. View

20.

Adam N, Rabe B, Suthaus J, Grotzinger J, Rose-John S, Scheller J . Unraveling viral interleukin-6 binding to gp130 and activation of STAT-signaling pathways independently of the interleukin-6 receptor. J Virol. 2009; 83(10):5117-26. PMC: 2682076. DOI: 10.1128/JVI.01601-08. View